PROGIT Film-coated tablet Ref.[11050] Active ingredients: Itopride

Publisher: PRO.MED.CS Praha a.s., Telฤskรก 377/1, Michle, 140 00 Praha 4, Czech Republic

4.1. Therapeutic indications

Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia, like feelings of bloating, gastric fullness, discomfort to pain in epigastrium, anorexia, heartburn, nausea and vomiting.

The medicinal product is intended for adults.

4.2. Posology and method of administration

Posology

The recommended dose for adults is 150 mg daily, i.e. 1 tablet 3 times a day before meal. This dose can be reduced if required in the course of disease. The exact dosage and duration of treatment depends on the clinical state of the patient. The duration of the administration in clinical studies was maximally 8 weeks.

Paediatric population

The safety and efficacy of itopride in paediatric population has not been established.

Patients with hepatic or renal impairment

Itopride is metabolised in liver. Itopride and its metabolites are excreted mainly via kidneys. Patients with reduced hepatic or renal functions should be carefully monitored and in case of adverse reactions it is necessary to take appropriate measures, as e.g. to reduce the dosage or to discontinue the therapy.

Elderly

It was shown in clinical studies that the incidence of adverse effects in patients aged 65 years and older was not higher than in younger patients. Itopride should be administered in elderly patients with adequate caution because of increased incidence of hepatic and renal function disorders, other diseases or treatment with additional drugs.

Method of administration

Tablets should be swallowed whole with a sufficient amount of liquid.

4.9. Overdose

Overdose was not experienced in humans. In case of overdose the usual measures of gastric lavage and symptomatic therapy should be applied.

6.3. Shelf life

5 years.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5. Nature and contents of container

OPA/Al/PVC/Al blister or transparent PVC/PVdC/Al blister, carton.

Pack size: 10, 20, 30, 40, 90 or 100 film-coated tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

No special requirements.

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.